Amgen, the nation’s biggest biotech company, reported fourth-quarter profits that beat analysts’ estimates, aided by a tax benefit and higher-than-estimated sales of arthritis drug Enbrel.
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
